OBI Pharma’s Board of Directors approves the announcement of the Company’s 2016 individual and consolidated financial statements
Date of the Event: 9 Mar 2017 Company Name: OBI Pharma, Inc Relationship to the Company (enter “Parent” or “Subsidiary”: Parent Reciprocal shareholding ratios: N/A Reason for the Event: The …
Supplemental Information: OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)
Date of occurrence of the event: January 26, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): Head office Reciprocal shareholding ratios: …
China FDA approves Clinical Trial Application for Adagloxad Simolenin Phase III Study
On 24 January 2017, OBI Pharma, Inc. (4174) received formal approval from the China Food and Drug Administration (CFDA) to conduct a proposed phase III clinical trial for Adagloxad Simolenin …
OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)
Date of occurrence of the event: January 25, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): Head office Reciprocal shareholding ratios: …
OBI Pharma Inc. announces the change of Chief Operating Officer
Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel(CEO, COO, CMO, CSO, etc.),financial officer, accounting officer, research and development officer, or internal audit officer): Chief Operating Officer Date …
Clarification on the news article by Commercial Times
Date of occurrence of the event: January 21, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A …
OBI Pharma holds EOP2 meeting with US FDA
OBI Pharma, Inc. has met with the Office of Tissues and Advanced Therapies (OTAT) of the US Food and Drug Administration (FDA) for its End-of-Phase 2 (EOP2) meeting for Adagloxad …
Clarification on the news article by United Daily News E-Paper
Date of occurrence of the event: January 11, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A …
OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence.
OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence. Shi-Lin District prosecutors Office announced today (9 Jan 2017) the result of the investigation of …
Clarification on the news article by Economic Daily News
Date of occurrence of the event: January 10, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A …